Clostridium News and Research

RSS

Some patients appear to be more predisposed for recurrent infection from C. diff

University of Cincinnati (UC) researchers have found that some patients appear to be more predisposed for recurrent infection from the bacterium Clostridium difficile, or C. diff, and that it may advance to a more serious inflammatory condition in those individuals.

22 May 2012

T cell imbalance may put certain people at increased risk of C. difficile infection

University of Cincinnati (UC) researchers have found that an imbalance in the regulation of certain T cells-the cells in the body that fight off infection or attack the system in certain autoimmune diseases-may put certain people at a higher risk of having recurrent cases of Clostridium difficile, or C. Diff, infection.

22 May 2012

Probiotics may reduce risk of antibiotic-associated diarrhea

Consumption of probiotics (live microorganisms, which may occur naturally in foods such as yogurt, intended to confer a health benefit when consumed) is associated with a reduced risk of antibiotic-associated diarrhea, a common adverse effect of antibiotic use, according to a review and meta-analysis of previous studies published in the May 9 issue of JAMA.

9 May 2012

Strong link between HAIs and patient readmission after initial hospital stay

New research finds a strong link between healthcare-associated infections (HAIs) and patient readmission after an initial hospital stay. The findings, published in the June 2012 issue of Infection Control and Hospital Epidemiology, the journal of the Society for Healthcare Epidemiology of America (SHEA), suggest that reducing such infections could help reduce readmissions, considered to be a major driver of unnecessary healthcare spending and increased patient morbidity and mortality.

5 May 2012

Synthetic stool transplant for C. difficile treatment

A synthetic mixture of intestinal bacteria could one day replace stool transplants as a treatment for Clostridium difficile (C. difficile). C. difficile is a toxin-producing bacteria that can overpopulate the colon when antibiotics eradicate other, naturally protective bacteria living there.

2 May 2012

FDA clears Great Basin’s first C. diff molecular diagnostic test

Great Basin Corporation, a privately-held life sciences company developing sample-to-result molecular diagnostic solutions, today announced that the U.S. Food and Drug Administration (FDA) has granted approval for its first molecular diagnostic test for Clostridium difficile.

2 May 2012

Amoxicillin-clavulanate may improve small bowel function in children experiencing motility disturbances

The common antibiotic, amoxicillin-clavulanate, may improve small bowel function in children experiencing motility disturbances, according to a study appearing in the June print edition of the Journal of Pediatric Gastroenterology and Nutrition from Nationwide Children's Hospital.

30 Apr 2012

Quest Diagnostics receives FDA clearance for Simplexa C. difficile Universal Direct test

Quest Diagnostics, the world's leading provider of diagnostic testing, information and services, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance to its Simplexa C. difficile Universal Direct Test on the 3M Integrated Cycler.

From Quest Diagnostics 12 Apr 2012

Akorn launches generic Vancocin for treatment of CDAD

Akorn, Inc., a niche specialty pharmaceutical company, today announced that it has launched Vancomycin Hydrochloride USP 125mg and 250mg capsules, the generic version of ViroPharma's Vancocin, which is indicated for the treatment of Clostridium difficile-associated diarrhea.

10 Apr 2012

Patients with community-onset CDI have increased risk of colectomy

Patients whose symptoms of Clostridium difficile infection (CDI) start outside of the hospital setting have a higher risk of colectomy due to severe infection, according to a large multicenter study funded by the Centers for Disease Control and Prevention (CDC) and published in Infection Control and Hospital Epidemiology, the journal of the Society for Healthcare Epidemiology of America.

5 Apr 2012

Ventria completes VEN100 phase 2 trial on antibiotic-associated diarrhea

Ventria Bioscience has announced the successful completion of a phase 2 clinical trial of its lead therapeutic candidate, VEN100. The study was conducted by a team of investigators from the Department of Epidemiology, Division of Infectious Diseases, and Division of Geriatric Medicine at Johns Hopkins University.

5 Apr 2012

Risk of botulism at California fish processing company

The U.S. Food and Drug Administration, in a complaint filed by the Department of Justice, is seeking to stop the processing and distribution of fish products at a California company because of a risk of botulism and other food hazards.

30 Mar 2012

FDA clears BD MAX assay for detecting GBS DNA in Lim Broth cultures

BD announced today the U.S. Food and Drug Administration clearance of the BD MAX Group B Streptococcus (GBS) Assay and Clinical Laboratory Improvement Amendments (CLIA) moderate complexity test categorization on the second-generation BD MAX System.

From BD (Becton, Dickinson and Company) 29 Mar 2012

New antibiotic shows promise against bovine mastitis

Food-borne diseases might soon have another warrior to contend with, thanks to a new molecule discovered by chemists at the University of Illinois. The new antibiotic, an analog of the widely used food preservative nisin, also has potential to be a boon to the dairy industry as a treatment for bovine mastitis.

20 Mar 2012

Fecal transplantation effective treatment for recurrent C. difficile infection

Fecal transplantation through colonoscopy is an effective treatment for recurrent Clostridium difficile infection (CDI), according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association.

15 Mar 2012

Simple device for disinfecting stethoscopes

According to the Centers for Disease Control and Prevention (CDC) 1,900,000 people contract infections in hospitals, (Hospital Acquired Infections - HAIs) every year and well over 99,000 die as a result; more deaths than from AIDS, breast cancer and auto accidents combined.

12 Mar 2012

Hospitals with infection control certification may have lower MRSA BSI rates

Hospitals whose infection prevention and control programs are led by a director who is board certified in infection prevention and control have significantly lower rates of methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections (BSI) than those that are not led by a certified professional, according to a new study published in the March issue of the American Journal of Infection Control, the official publication of APIC - the Association for Professionals in Infection Control and Epidemiology.

12 Mar 2012

Combined bioactive peptides successfully stimulate wound healing

Researchers have combined bioactive peptides to successfully stimulate wound healing. The in vitro and in vivo study, published today in PLoS ONE, demonstrates that the combination of two peptides stimulates the growth of blood vessels and promotes re-growth of tissue. Further development of these peptides could lead to a new treatment for chronic and acute wounds.

24 Feb 2012

Actelion, Auxilium partner to develop and commercialize XIAFLEX

Auxilium Pharmaceuticals, Inc. and Actelion Pharmaceuticals Ltd. announced today that they have entered into a long-term partnership for the development, supply and commercialization of XIAFLEX (collagenase clostridium histolyticum), a novel, first-in-class biologic for the potential treatment of Dupuytren's contracture and Peyronie's disease.

23 Feb 2012

Patient feedback on how NHS hospitals are doing important

Patients are reportedly happy with the services they received at the Weston General Hospital outpatient department. The survey of 850 patients revealed Weston Area Health NHS Trust has improved in 13 areas since the last survey in 2009 and performs significantly better than other NHS trusts in 12 areas.

15 Feb 2012